Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors.
Christine L KemptonPeter TraskAric ParnesMarkus NiggliAvrita Campinha-BacoteMichael U CallaghanNiamh O'ConnellIdo Paz-PrielJohnny N MahlanguPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2021)
These results demonstrate that emicizumab prophylaxis leads to greater treatment satisfaction compared with FVIII prophylaxis, reflecting in part the low treatment burden of emicizumab associated with its infrequent, SC administration.
Keyphrases